Gilead Sciences, Inc. $GILD Shares Sold by Aviance Capital Partners LLC

Aviance Capital Partners LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 4,796 shares of the biopharmaceutical company’s stock after selling 422 shares during the period. Aviance Capital Partners LLC’s holdings in Gilead Sciences were worth $532,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Syverson Strege & Co acquired a new stake in Gilead Sciences in the second quarter valued at $327,000. NWK Group Inc. raised its holdings in Gilead Sciences by 341.4% in the second quarter. NWK Group Inc. now owns 66,080 shares of the biopharmaceutical company’s stock valued at $7,326,000 after acquiring an additional 51,108 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in Gilead Sciences by 0.4% in the second quarter. Pinnacle Associates Ltd. now owns 101,816 shares of the biopharmaceutical company’s stock valued at $11,288,000 after acquiring an additional 434 shares in the last quarter. Putney Financial Group LLC raised its holdings in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. Finally, Simon Quick Advisors LLC raised its holdings in Gilead Sciences by 210.1% in the second quarter. Simon Quick Advisors LLC now owns 27,392 shares of the biopharmaceutical company’s stock valued at $3,037,000 after acquiring an additional 18,558 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on GILD. Wolfe Research boosted their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 target price on shares of Gilead Sciences in a research note on Friday. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a research note on Friday. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research note on Tuesday, August 19th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $123.87.

Gilead Sciences Stock Up 1.1%

Gilead Sciences stock opened at $119.79 on Friday. The company has a 50-day simple moving average of $115.66 and a 200-day simple moving average of $111.61. The firm has a market capitalization of $148.64 billion, a P/E ratio of 23.86, a P/E/G ratio of 0.81 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.61.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This represents a 1.66% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 71,500 shares of company stock worth $8,336,040. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.